{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:03:20Z","timestamp":1787501000089,"version":"build-2736575974"},"reference-count":21,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The use of immunomodulatory and immunosuppressive therapies in multiple sclerosis (MS) has allowed practitioners to regulate MS disease activity, with the caveat that these potent medications may render patients susceptible to opportunistic infections. The approval of fingolimod presented the first oral option for relapsing MS. Since 2015, postmarketing safety data have documented several published cases of cryptococcal meningitis and disseminated cryptococcosis associated with fingolimod use. However, surveillance mechanisms for opportunistic infections and management of active demyelinating disease with ongoing infection have not been adequately addressed. We present a case of isolated pulmonary cryptococcosis with the use of fingolimod to highlight the hurdles in balancing efficacious disease-modifying therapies for MS while treating an opportunistic infection associated with that therapy.<\/jats:p>","DOI":"10.7224\/1537-2073.2018-080","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T16:07:00Z","timestamp":1547568420000},"page":"275-280","source":"Crossref","is-referenced-by-count":23,"title":["Case Report: Fingolimod and Cryptococcosis"],"prefix":"10.7224","volume":"21","author":[{"given":"Rohini D.","family":"Samudralwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Spec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne H.","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4242","reference":[{"key":"2020060300350786100_i1537-2073-21-6-275-b1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaneurol.2015.1746","article-title":"Cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod","volume":"72","author":"Achtnichts","year":"2015","journal-title":"JAMA Neurol"},{"key":"2020060300350786100_i1537-2073-21-6-275-b2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"2020060300350786100_i1537-2073-21-6-275-b3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"2020060300350786100_i1537-2073-21-6-275-b4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol"},{"key":"2020060300350786100_i1537-2073-21-6-275-b5","doi-asserted-by":"crossref","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","article-title":"Progressive multifocal leukoencephalopathy after fingolimod treatment","volume":"90","author":"Berger","year":"2018","journal-title":"Neurology"},{"key":"2020060300350786100_i1537-2073-21-6-275-b6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.msard.2016.07.015","article-title":"Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: a case report and review of literature","volume":"9","author":"Grebenciucova","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"2020060300350786100_i1537-2073-21-6-275-b7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-444-63849-6.00011-6","article-title":"Cryptococcal meningitis in AIDS","volume":"152","author":"Spec","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"2020060300350786100_i1537-2073-21-6-275-b8","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","article-title":"Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study","volume":"89","author":"Wijnands","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2020060300350786100_i1537-2073-21-6-275-b9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.msard.2015.06.005","article-title":"GLACIER: an open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis","volume":"4","author":"Wolinsky","year":"2015","journal-title":"Mult Scler Relat Disord"},{"key":"2020060300350786100_i1537-2073-21-6-275-b10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/jim-2016-000339","article-title":"Update on disease-modifying therapies for multiple sclerosis","volume":"65","author":"Vargas","year":"2017","journal-title":"J Investig Med"},{"key":"2020060300350786100_i1537-2073-21-6-275-b11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40120-017-0064-x","article-title":"Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims database","volume":"6","author":"Boster","year":"2017","journal-title":"Neurol Ther"},{"key":"2020060300350786100_i1537-2073-21-6-275-b12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/03007995.2016.1248380","article-title":"Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis","volume":"33","author":"Fox","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"2020060300350786100_i1537-2073-21-6-275-b13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"2020060300350786100_i1537-2073-21-6-275-b14","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.2169\/internalmedicine.55.7255","article-title":"Disseminated cryptococcosis in a 63-year-old patient with multiple sclerosis treated with fingolimod","volume":"55","author":"Seto","year":"2016","journal-title":"Intern Med"},{"key":"2020060300350786100_i1537-2073-21-6-275-b15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jamaneurol.2015.4259","article-title":"Primary cutaneous cryptococcus in a patient with multiple sclerosis treated with fingolimod","volume":"73","author":"Forrestel","year":"2016","journal-title":"JAMA Neurol"},{"key":"2020060300350786100_i1537-2073-21-6-275-b16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.msard.2016.06.007","article-title":"Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis","volume":"9","author":"Ward","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"2020060300350786100_i1537-2073-21-6-275-b17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.inat.2017.10.005","article-title":"Refractory cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod: a case report","volume":"12","author":"Anene-Maidoh","year":"2018","journal-title":"Interdisciplinary Neurosurgery"},{"key":"2020060300350786100_i1537-2073-21-6-275-b18","article-title":"Cryptococcal meningitis causing obstructive hydrocephalus in a patient on fingolimod","volume":"2017","author":"Pham","year":"2017","journal-title":"BMJ Case Rep"},{"key":"2020060300350786100_i1537-2073-21-6-275-b19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1212\/WNL.0000000000001929","article-title":"Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod","volume":"85","author":"Huang","year":"2015","journal-title":"Neurology"},{"key":"2020060300350786100_i1537-2073-21-6-275-b20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.msard.2017.11.013","article-title":"Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: a combined perspective from the MS in the 21st Century Steering Group","volume":"19","author":"Members of the MS in the 21st Century Steering Group","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"2020060300350786100_i1537-2073-21-6-275-b21","first-page":"558","article-title":"Impact of infectious diseases consultation on mortality of cryptococcal infection in patients without HIV","volume":"64","author":"Spec","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/21\/6\/275\/2487931\/1537-2073_2018-080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/21\/6\/275\/2487931\/1537-2073_2018-080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:12:47Z","timestamp":1752786767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/case-report-fingolimod-and-cryptococcosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2018-080","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}